Nombre total de rapports de communication : 28
Rapports mensuels de communications au cours des 6 derniers mois : 0
Reckitt Benckiser Pharmaceuticals Inc. is committed to optimizing standards of patient care and minimizing risks of diversion and abuse through programs of education and intervention that we believe represent a benchmark for the pharmaceutical industry in the therapeutic area of addiction treatment. Our Risk Management Program includes educational efforts that emphasize the safe and effective use of buprenorphine and are directed toward physicians, pharmacists, counselors, and patients and their families. All educational materials developed by Reckitt Benckiser Pharmaceuticals Inc. focus on reinforcing the matrix of care model to provide patients and their treatment providers with information that supports best medical practices. Our comprehensive educational endeavors are intended to educate healthcare providers and patients on the proper use as well as the risks associated with Suboxone and Subutex sublingual tablets.
Gary Phillips, President & CEO (North America)
Adresse :
10710 Midlothian Turnpike
Richmond, VA 23235
États-Unis d'Amérique
Numéro de téléphone :
804-379-1090
Numéro de fax :
804-379-1215
Reckitt Benckiser Pharmaceuticals Inc. / Reckitt Benckiser Pharmaceuticals Inc ne possède aucune filiale qui pourrait être directement intéressée au résultat de l'engagement